ReviewDrugs in context2023
Antifungal resistance, combinations and pipeline: oh my!
Review in Drugs in context, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcriptomic meta-analysis to identify potential antifungal targets in Candida albicans.BMC microbiology · 2024Pooled it
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Antifungal Activity of Selected Naphthoquinones and Their Synergistic Combination with Amphotericin B AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Antifungal activity of guanidine compounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Mono-Antibiotics (Basel, Switzerland) · 2024Article
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides.International journal of molecular sciences · 2024Review
- In vitro antifungal activity of MMV Pathogen Box® compounds alone or in combination with antifungal drugs against mucormycosis agents.Current research in microbial sciences · 2024Article
- The top 10 papers on the treatment of invasive fungal infections, 2018-2023.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.